Inhibition of anti-apoptotic BCL-2 (B-cell lymphoma 2) has recently emerged as a promising new therapeutic strategy for the treatment of a variety of human cancers, including leukemia. Here, we used T-cell acute lymphoblastic leukemia (T-ALL) as a model system to identify novel synergistic drug combinations with the BH3 mimetic venetoclax . In vitro drug screening in primary leukemia specimens that were derived from patients with high risk of relapse or relapse and cell lines revealed synergistic activity between venetoclax and the BET (bromodomain and extraterminal) bromodomain inhibitor JQ1. Notably, this drug synergism was confirmed in vivo using T-ALL cell line and patient-derived xenograft models. Moreover, the therapeutic benefit of this drug combination might, at least in part, be mediated by an acute induction of the pro-apoptotic factor BCL2L11 and concomitant reduction of BCL-2 upon BET bromodomain inhibition, ultimately resulting in an enhanced binding of BIM (encoded by BCL2L11) to BCL-2. Altogether, our work provides a rationale to develop a new type of targeted combination therapy for selected subgroups of high-risk leukemia patients.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell progenitors and accounts for about 15% of childhood and 25% of adult ALL cases. 1 The cure rate for childhood T-ALL has steadily increased over the past decades, with current survival rates reaching ∼ 85%. 2, 3 Although these numbers are high, the clinical perspective for children who fail induction therapy or suffer from relapsed disease remains extremely poor, with only a 7-23% subset of relapsed T-ALL patients surviving beyond 3 to 5 years after the initial diagnosis. 4 Compared with childhood leukemia, the clinical picture for adult T-ALL is even worse, with high relapse rates and long-term disease-free survival of ∼ 40%. [5] [6] [7] Altogether, these figures suggest that better and less toxic treatment strategies are urgently required to further improve the clinical management of childhood and adult T-ALL patients.
Recently, we and other research groups reported promising therapeutic activity for venetoclax (ABT-199), a highly specific inhibitor of the anti-apoptotic protein BCL-2 (B-cell lymphoma 2), in immature subtypes of human T-ALL. [8] [9] [10] Nevertheless, venetoclax sensitivity is variable between different T-ALL patient samples and the emergence of resistance to venetoclax [11] [12] [13] as well as the occurrence of dose-limiting toxicities 14 provides a rationale for the evaluation of venetoclax as part of a combination therapy. Indeed, previous studies have shown that venetoclax can synergize with conventional chemotherapeutic agents in human T-ALL, including doxorubicin, L-asparaginase, dexamethasone and cytarabine. 8, 9 Venetoclax has recently also been approved by the FDA (Food and Drug Administration) for the treatment of chronic lymphocytic leukemia. Indeed, clinical trials demonstrated progress-free survival in more than two-thirds of relapsed chronic lymphocytic leukemia patients, 14 including poor prognostic chronic lymphocytic leukemia patients who carry a 17p deletion. 15 Nevertheless, complete remission remained uncommon, 14 further reinforcing the need for the evaluation of combined therapeutic strategies.
Bromodomains of the bromodomain and extraterminal (BET) protein family recognize ε-N-acetylation of lysine residues on histone tails. BRD4 is an important BET protein that recruits the positive transcription elongation factor complex (P-TEFb) to acetylated chromatin. 16 The transcriptional coactivators BRD4 and Mediator co-occupy enhancers and promoters of active genes and are enriched at large stretches of enhancer sequences, often termed super-enhancers. [17] [18] [19] Notably, these enhancers regulate the expression of critical oncogenes in a variety of human cancers, providing a rationale for the use of BET bromodomain inhibitors, such as JQ1, as powerful anticancer agents. [17] [18] [19] In addition, in T-ALL, BET bromodomain inhibitors have shown therapeutic efficacy in a number of in vitro and in vivo model systems and were shown to inhibit the expression of the T-ALL oncogene MYC. [20] [21] [22] Furthermore, super-enhancers have been identified in a panel of T-ALL cell lines near putative oncogenes, including MYB, TAL1, CDK6 and NOTCH1. 18 In this study, we identified synergistic drug combinations with the BH3 mimetic venetoclax in the context of human T-ALL. Most notably, we show that combined targeting of BCL-2 and BET bromodomain proteins synergistically affects leukemic tumor growth in T-ALLs that were resistant to conventional chemotherapeutic agents.
MATERIALS AND METHODS

Primary patient samples
Primary human ALL cells were recovered from cryopreserved bone marrow aspirates of patients enrolled in the ALL-BFM 2000, 2009 and ALL-REZ-BFM 2002 study. Informed consent was given in accordance with the Declaration of Helsinki and the ethics commission of the Kanton Zurich (approval number 2014-0383). Samples were classified as standard risk, medium risk, high risk, very high risk or relapse samples according to the clinical criteria used in ALL-BFM 2000. 23 
Drug-screening platform
The in vitro drug response of T-ALL primary patient samples was assessed in co-culture with hTERT-immortalized primary bone marrow mesenchymal stromal cells as described previously. 23 Details are provided in the Supplementary Data.
Cell lines
Cell lines were purchased from the DSMZ repository (Braunschweig, Germany), except for CUTLL1 (gift from Professor Adolfo Ferrando, Columbia University, New York, NY, USA) and KOPTK1 (gift from Professor Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY, USA). Cells were cultured in RPMI-1640 medium (52400-025; Life Technologies, Carlsbad, CA, USA) supplemented with 10 or 20% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin (15140-148; Life Technologies), 100 μg/ml kanamycin sulfate (15160-047; Life Technologies) and 2 mM L-glutamine (25030024; Life Technologies) at 37°C with 5% CO 2 .
In vitro evaluation of synergism between venetoclax and JQ1 in human T-ALL cell lines and primary samples
The 48 h treatment of the cell lines with venetoclax (2253-1; BioVision, Milpitas, CA, USA) and/or (+)-JQ1 (27401; BPS Bioscience, San Diego, CA, USA) and viability measurements via the CellTiter Glo Viability assay (Promega, Madison, WI, USA) were done as described in Peirs et al. 8 CalcuSyn software (Biosoft, Cambridge, UK) was used to calculate the combination index (CI) with the Chou-Talalay method. The reported CI is the average of the values obtained at the effective dose (ED) points ED 50 , ED 75 and ED 90 . Primary patient samples co-titration experiments were performed for selected drugs. T-ALL cell plates were prepared and handled in the same manner as for drug combination screening described above. Selected drugs in combination with venetoclax were dispensed using Tecan D300 digital dispenser (Tecan Group, Männedorf, Switzerland) in a concentration matrix. The concentration range tested for venetoclax and JQ1 were determined for each patient based on initial drug response screening. CI was calculated using Chou-Talalay method as implemented in R package (https://github.com/xtmgah/DDCV).
Western blot
Western blot analysis was performed as previously described. 8 The primary antibodies used were Bcl-2 antibody (C-2; 1:500, sc-7382; Santa Cruz Biotechnology, Dallas, TX, USA), PARP-1 antibody (F-2; 1:1000, sc-8007; Santa Cruz Biotechnology), BIM antibody (1:1000, AB17003; EMD Millipore, Darmstadt, Germany), β-actin antibody (1:10 000, Clone AC-75, A2228; Sigma-Aldrich, St Louis, MO, USA) and α-tubulin antibody (1:10 000, T5168; Sigma-Aldrich). The detection of the blots was done with ChemiDoc-It Imaging System (UVP, Upland, CA, USA). Densitometric analysis of the protein bands was performed using ImageJ (NIH, Bethesda, MD, USA). Images have been cropped for presentation.
Annexin V/propidium iodide staining FITC Annexin V Apoptosis Detection Kit I (556547; BD Biosciences, San Jose, CA, USA) was used and samples were measured on the S3 cell sorter (BioRad, Hercules, CA, USA). Gene expression profiling and GSEA LOUCY cells were treated with dimethyl sulfoxide or (+)-JQ1. Three biological replicates of this treatment were performed and RNA was isolated using the miRNeasy mini kit (Qiagen, Venlo, The Netherlands) with on-column DNase digestion. RNA quality was evaluated by the Experion RNA StdSens analysis kit (Bio-Rad). RNA was amplified and labeled using the Low Input Quick Amp Labeling Kit, One Color (5190-2305; Agilent Technologies, Santa Clara, CA, USA) and hybridized with the Gene Expression Hybridization Kit (5188-5242; Agilent Technologies) to the SurePrint G3 Human Gene Expression Microarray G4851A (design ID 028004, Agilent Technologies). Normalization of microarray intensities was done using the variance stabilization and calibration (VSN, Bioconductor release 3.30.0) package in R software (version 3.0.2). 24 Only probes with a signal 10% higher than the negative control probes were considered for analysis. Differential expression analysis was performed using the limma package (Bioconductor release 3.18.13) with P-value adjustment using the Benjamini and Hochberg method. The design matrix took into account the pairing information of the data. Enrichment analysis was performed with the Molecular Signatures database (MSigDB) c2 gene sets collection using the GSEA (Gene Set Enrichment Analysis) desktop application (version 2.2.0, Broad Institute, Cambridge, MA, USA)) run with the default parameters and with gene set permutations. The data have been deposited in NCBI Gene Expression Omnibus (GEO) 25 and are accessible through GEO Series accession number GSE81918.
Real-time quantitative PCR
The miRNeasy mini kit (Qiagen) and the RNase-Free DNase set (Qiagen) were used to isolate RNA. For determination of mRNA levels, complementary DNA (cDNA) synthesis was performed with the iScript Advanced cDNA synthesis kit (Bio-Rad). The SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used for the PCR reactions. Every sample was analyzed in duplicate and the gene expression was normalized against three housekeeping genes. For quantification of mature microRNAs, the miScript II RT kit (Qiagen) and target-specific miScript Primer Assays (Qiagen) together with the miScript SYBR Green PCR Kit were used. All real-time quantitative PCR reactions were run on the LightCycler 480 (Roche, Vilvoorde, Belgium) and qBasePLUS software (Biogazelle, Zwijnaarde, Belgium) was used for analysis. Primer sequences and miScript Primer Assays are listed in Supplementary Table 5 .
Co-immunoprecipitation
Protein lysates were incubated with 2 μg of antibody. After 4 h of rotation at 4°C, 20 μl of Protein A UltraLink Resin (53139; Thermo Scientific, Waltham, MA, USA) was added for overnight incubation at 4°C. Beads were washed 3 times with RIPA buffer and immunoprecipitates were eluted by heating the beads at 95°C in 2 × SDS loading buffer (62 mM TrisHCl (pH 6.8), 4% SDS, 20% glycerol, 0.01% BFB (bromophenol blue) and 2.5% β-mercaptoethanol) for 10 min. A part of the original lysates were similarly denaturated by heating at 95°C for 10 min after adding 5 × SDS Combination of venetoclax and JQ1 in T-ALL S Peirs et al loading buffer (155 mM Tris-HCl (pH 6.8), 5% SDS, 32% glycerol, 0.025% BFB and 2.5% β-mercaptoethanol).
Modulation of BIM expression
The pENTR223-BCL2L11 (LMBP ORF81079-A09) plasmid was available from the BCCM/LMBP Plasmid Collection 26 and was used to clone BCL2L11 in the pInducer21 plasmid. 27 The MISSION lentiviral shBCL2L11 TRCN0000001051 (Sigma-Aldrich) vector (BCCM/LMBP Collection 26 ) , in which the puromycin resistance cassette was replaced by eGFP, was used to perform BIM knockdown. As nontargeting small hairpin RNA control, MISSION pLKO. 1-puro Non-Mammalian small hairpin RNA Control Plasmid (SHC002), in which puro was also replaced by eGFP, was used. Virus production was performed in HEK293TN cells using JetPEI polyplus with pMD2.G (envelope plasmid
Statistics
GraphPad Prism 5.04 (La Jolla, CA, USA) was used for statistical analyses.
RESULTS
Identification of synergistic drug combinations with venetoclax in primary human T-ALL Previous studies have shown promising antitumor activity for venetoclax in the context of human T-ALL. [8] [9] [10] However, drug responses have been variable across patients both in vitro and in xenografts, suggesting the need for predictive biomarkers and further investigation toward synergistic drug combinations with venetoclax. Given this, we took advantage of a drug-profiling platform 28, 29 ( Figure 1a ) to test 21 clinically relevant compounds (Supplementary Table 1 venetoclax in six primary human T-ALLs, including five diagnostic and one relapse specimen. Notably, the selected patient samples represented different molecular genetic subtypes of human T-ALL and displayed a variety of tumor immunophenotypes. In addition, they displayed variable levels of BCL-2 and BIM protein expression (Supplementary Figure 1a) and most of these high-risk T-ALL patient samples experienced significant levels of minimal residual disease upon first-line therapy (Supplementary Table 2) .
First, we generated venetoclax response curves for each T-ALL sample and selected a sublethal dose of venetoclax for screening purposes (Figure 1a) . Two T-ALL samples were sensitive at concentrations below 100 nM, whereas the remaining cases were more resistant to venetoclax (Supplementary Figure 1b) . This variability in venetoclax sensitivity amongst T-ALL patient samples corresponded to large differences in the area under the curve, a parameter that captures both IC 50 (half-maximal inhibitory concentration) and E max (maximal efficacy) as relevant end points of drug activity (Figure 1b) . Next, we generated dose response curves (1 nM, 10 nM, 100 nM, 1 μM and 10 μM) for the 21 compounds in the presence or absence of a sublethal dose of venetoclax (Figure 1a) . The results of this initial screening are visualized by scatterplots of area under the curve values, in which decreased area under the curve upon addition of venetoclax is indicative of increased antileukemic activity (Figure 1b and Supplementary  Figure 2 ). In line with previous studies, the combination of venetoclax with conventional chemotherapeutic agents including vincristine, dexamethasone and etoposide increased therapeutic efficacy in some of the T-ALL cases analyzed (Figure 1b) . The strongest effects, however, were observed for the combination of venetoclax with JQ1 that resulted in reduced leukemic tumor growth in 5 out of 6 primary T-ALL patient samples (Figure 1b) . As a confirmation, we validated responsive (Figure 1c ) as well as nonresponsive (Supplementary Figure 3) drug interactions identified in this initial screen. Altogether, this screening effort identified clinically relevant drugs that could increase the therapeutic efficacy of venetoclax in the context of T-ALL.
Combined targeting of BCL-2 and BET bromodomain proteins in human T-ALL Given that our initial screen pointed toward increased efficacy of venetoclax upon BET bromodomain inhibition in a significant proportion of T-ALLs, we subsequently analyzed the synergistic potential of this drug combination in more detail by performing co-titration experiments with individually optimized concentration ranges in primary leukemias and a panel of human T-ALL cell lines.
First, we determined the CIs for the six primary T-ALLs that were also used for the initial screening and identified synergistic activities (CI o 1) between venetoclax and JQ1 in five out of six cases analyzed (Figure 2a) . Notably, similar results were obtained using OTX015 (MK-8628), another BET bromodomain inhibitor currently being tested in clinical trials for various tumor entities 30, 31 (Supplementary Figure 4) . Next, we determined dose response curves in a panel of 13 human T-ALL cell lines with different BCL-2 levels and varying sensitivities toward venetoclax (Figure 2b and Supplementary Figure 5) . Notably, T-ALL cell lines displayed variable levels of synergism with the lowest CI values (strongest synergism) detected for tumor lines with high BCL-2 expression (Figure 2b) . Indeed, the CI showed a negative correlation with BCL-2 protein levels in T-ALL cell lines (Figure 2c) . Moreover, synergistic activity of this drug combination corresponded to increased cell death induction in T-ALL cell lines with low CI values (Supplementary Figure 6) .
Evaluation of the venetoclax and JQ1 combination therapy in xenograft models
To evaluate the therapeutic potential of combined BCL-2 and BET bromodomain inhibition in human T-ALL, we subsequently performed in vivo drug treatment experiments using xenograft models. At 4 weeks after injection of luciferase-positive LOUCY cells 8 in immunodeficient mice, successful engraftment was confirmed by bioluminescence imaging and daily drug treatment was initiated (days 1-13). Leukemia still progressed under JQ1 monotherapy (n = 5), although to a lesser extent as compared with vehicle-treated control mice (n = 8; Figure 3a and Supplementary  Figure 7) . Mice treated for 13 days with venetoclax alone (n = 5) initially showed disease regression, but this therapeutic response was not durable (Figure 3a and Supplementary Figure 7) . In contrast, combination of venetoclax with JQ1 (n = 5) resulted in durable disease regression (Figures 3a and b Combination of venetoclax and JQ1 in T-ALL S Peirs et al Figure 8 ), a putative side effect of BET bromodomain inhibition. The synergistic effect of combined BCL-2 and BET bromodomain inhibition was also confirmed in the TLX1-positive T-ALL cell line ALL-SIL (Supplementary Figure 9) . The genetic characteristics of LOUCY and ALL-SIL are summarized in Supplementary Table 3 .
Finally, we performed a similar in vivo drug treatment experiment using a primary patient-derived xenograft. For this, leukemic cells from the very high risk T-ALL patient (T-VHR-26) were engrafted and treated with a similar drug regimen as mentioned above. Notably, this experiment confirmed the superior Combination of venetoclax and JQ1 in T-ALL S Peirs et al therapeutic effect of combined BCL-2 and BET bromodomain inhibition for the treatment of this high risk T-ALL patient sample (Figure 4 and Supplementary Figure 10) . Of note, in this experiment, no significant weight loss was observed in any of the treatment groups (Supplementary Figure 10c) .
Mechanistic insights into the synergistic activities of venetoclax and JQ1 in human T-ALL To understand how BET bromodomain inhibition might synergize with the BCL-2 inhibitor venetoclax, we subsequently analyzed the transcriptional consequences of JQ1 treatment in the T-ALL cell line LOUCY by microarray analysis. Short-term exposure to a low dose of JQ1 (4 h, 250 nM) provided insights into the genes whose expression was immediately affected by BET bromodomain inhibition (Figure 5a, left) . In contrast, sustained exposure at a higher concentration (48 h, 1 μM) revealed broader transcriptional effects with more than half of the expressed probe sets showing significant up-or downregulation (adjusted P-value o0.05; Figure 5a , right). Significantly downregulated genes upon shortterm drug treatment included stem-cell associated genes and putative oncogenes such as BAALC, WT1, MN1, MEF2C, LMO1 and LMO2, whereas other oncogenic factors, including BCL2, IGFBP7, ZEB2, GFI1B, MYB and LYL1, only changed significantly after 48 h.
In line with previous reports, [17] [18] [19] these JQ1-responsive genes were regulated by strong and active enhancer elements characterized by broad binding of the H3K27ac histone mark in LOUCY cells 32 ( Figure 5b ). Indeed, genes associated with the 500 highest ranked enhancer regions in LOUCY were significantly enriched in genes downregulated after JQ1 treatment (Figure 5c ). Moreover, enrichment analysis using gene sets from the MSigDB revealed that genes upregulated after JQ1 in LOUCY cells significantly overlapped with genes activated upon histone deacetylase (HDAC) inhibition (Figure 5d ). In line with this notion, the LINCS (Library of Integrated Cellular Signatures) revealed a strong connection between the JQ1-induced expression signature in LOUCY and gene signatures induced by HDAC inhibitors (Supplementary Table 4 ).
Given that binding of the pro-apoptotic BIM (encoded by BCL2L11) to the BH3 domain of BCL-2 is an important mediator of venetoclax activity, [33] [34] [35] [36] we subsequently focused on the transcriptional effects of JQ1 on the expression of both factors. Notably, in LOUCY cells, BCL2L11 expression was induced after short-term JQ1 exposure (Figure 5a, left) , whereas downregulation of BCL2 expression was only detected at later time points (Figure 5a, right) . In addition, the expression of the miR17-92 cluster, a known negative regulator of BIM, 37 was not affected after 4 h of JQ1 treatment but was clearly downregulated after 48 h (Supplementary Figure 11a) . Upregulation of pro-apoptotic BCL2L11 and concomitant downregulation of anti-apoptotic BCL2 could be confirmed in all T-ALL cell lines that displayed strong synergy (CI o0.5) for the ABT199/JQ1 drug combination. As a result, BET bromodomain inhibition triggered an increased BIM to BCL-2 ratio (Figure 6a and Supplementary Figure 11b) , providing a putative explanation for the improved therapeutic efficacy of venetoclax upon JQ1 treatment. Indeed, co-immunoprecipitation experiments demonstrated an increased BIM to BCL-2 binding (Figure 6b ) upon JQ1 treatment. Finally, doxycycline-inducible overexpression of BIM in the KARPAS-45 cell line mimicked the effect of JQ1 and resulted in an increased sensitivity toward venetoclax (Figure 6c ), whereas knockdown of BIM lowered the sensitivity to ABT-199, JQ1 and combination treatment (Figure 6d ).
DISCUSSION
Venetoclax is a promising new molecular therapy that is currently being evaluated in clinical trials for different hematological malignancies. 14, 15, 38 However, the limited number of complete remissions 14 and the emergence of resistance with venetoclax as single agent prompts for a systematic evaluation of combinations with rationally designed small molecules to assess its true therapeutic potential. Indeed, synergistic cytotoxic effects have been described for the combination of venetoclax with BTK, [39] [40] [41] galectin, 42 aurora kinase A, 43 cyclin-dependent kinase 44, 45 and PI3K/AKT/mTOR (phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin) inhibition. 13, 46 Given the promising single-agent activity of venetoclax in human T-ALL subsets, [8] [9] [10] we systematically evaluated clinically relevant drugs in order to identify synergistic combinations with venetoclax. The strongest and most consistent effect was detected for the combination with the bromodomain inhibitors JQ1 and OTX015, both targeting critical mechanisms that are deregulated in cancer cells. This effect could be validated in vivo using leukemia xenograft models. Notably, this concept has recently been suggested as an experimental therapy for double-hit lymphoma, triple-hit lymphoma and mantle cell lymphoma in which both MYC and BCL2 are deregulated. [47] [48] [49] Interestingly, our preclinical data indicate that relevant activity can be obtained with this combination of agents irrespective of their activity as single agent that may possibly broaden the cohort of eligible cancer types (or subsets) for clinical translation. However, the challenge will be to identify useful biomarkers to better define patients who may benefit from such experimental combinations. Interestingly, an increase of BCL-2 protein levels in human T-ALL cell lines correlated with synergism between venetoclax and JQ1. Nevertheless, the value of additional methodologies such as BH3-profiling 50 should also be taken into consideration in future studies of this therapeutic rationale.
The importance of BRD4 in processes that lead to abnormal activation of cancer driving genetic programs is increasingly being understood. [17] [18] [19] The proof of concept in T-ALL was provided by studies of BET bromodomain inhibitors with a focus on MYC inhibition. [20] [21] [22] Given the central importance of super-enhancer deregulation in cancer, 18, 19 a similar principle may apply to many different transcriptional programs in leukemia cells. However, the broad transcriptional effects of these inhibitors on T-ALL cells remain largely unexplored. Gene expression profiling of LOUCY cells treated with JQ1 confirmed that BET bromodomain inhibition results in reduced expression of super-enhancer-associated oncogenes as previously described by Lovén et al. 17 Similar effects have also previously been reported for the T-ALL cell line ALL-SIL. 51 Although there is some overlap between superenhancers in different T-ALL cell lines, 18 ,51 each cell line seems to have a pretty unique spectrum of super-enhancer sequences. However, we also observed acute gene activation within 4 h of JQ1 treatment. In the gene signature that was activated upon JQ1 treatment in LOUCY cells, HDAC inhibitor-associated gene sets were enriched. This is in accordance with Bhadury et al. 52 who describe a large overlap between genes induced by BET and HDAC inhibitors.
BCL2L11 (encoding BIM) is one of the genes that showed such an acute induction of gene expression upon JQ1 treatment in the context of T-ALL. BIM is an activator BH3-only pro-apoptotic protein that can directly interact with BAX and/or BAK to induce apoptosis. BCL-2 can prevent apoptosis by sequestering proapoptotic proteins such as BIM. 53 Studies demonstrated the requirement for BCL-2 complexed to the pro-apoptotic activator BIM in order to sensitize lymphoid cells to BCL-2 inhibition by venetoclax or ABT-737. [33] [34] [35] [36] In our study, BET bromodomain inhibition increased BIM to BCL-2 binding, and could provide a putative explanation for the observed synergism between venetoclax and JQ1/OTX015 in the context of human T-ALL. Importantly, upregulation of pro-apoptotic BIM upon JQ1 treatment has also been described in a variety of other tumor entities, 47, [54] [55] [56] suggesting that the synergistic activity between these molecules might not be restricted to human T-ALL. Xu et al. 57 attributed the upregulation of BCL2L11 in response to JQ1 to the downregulation of the miR17-92 cluster. We also observed a downregulation of the miR17-92 cluster but not yet after 4 h of JQ1 treatment, a time point with already significant upregulation of BCL2L11 in LOUCY. Therefore, this mechanism does not explain the acute upregulation of BCL2L11 but this could definitely contribute to sustain the upregulation of BCL2L11.
In summary, our study provides a rationale to select patients with treatment-resistant T-ALL for an innovative combination treatment based on mechanisms that are not exploited by conventional chemotherapy regimens. Interference with the balance between pro-and anti-apoptotic proteins in BCL2-dependent T-ALL using the combination BET bromodomain inhibition and the BCL-2 inhibitor venetoclax should be considered in future clinical trials for this indication.
